资源中心
博客
与我们共同探索 RNA 领域前沿——尖端科学、技术突破与行业洞察。
Demand for nucleic acid therapeutics (NATs) is increasing as mRNA-based products, oligonucleotide therapeutics and gene editing applications expand from niche rare diseases into mainstream, high-prevalence indications. An example of this is Zilebesiran, a novel RNA interference (RNAi) therapeutic that is currently advancing through late-stage clinical trials for the treatment of hypertension [1]. This illustrates a […]
This article explores the limitations of SPOS, and provides an overview of chemoenzymatic ligation, its mechanism, and comparative advantages in siRNA and sgRNA synthesis.
Jul 8, 2026David Butler, CTO
Demand for nucleic acid therapeutics (NATs) is increasing as mRNA-based products, oligonucleotide therapeutics and gene editing applications expand from niche rare diseases into mainstream, high-prevalence indications. An example of this is Zilebesiran, a novel RNA interference (RNAi) therapeutic that is currently advancing through late-stage clinical trials for the treatment of hypertension [1]. This illustrates a […]
Mar 18, 2025David Butler, CTO
This article explores the limitations of SPOS, and provides an overview of chemoenzymatic ligation, its mechanism, and comparative advantages in siRNA and sgRNA synthesis.
- 10 / 页
- 20 / 页
- 50 / 页